arrow
M

Masakazu Toi

kyoto university
H指数:2
被引数:294

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A case of ER-positive, HER2-negative metastatic breast cancer with high tumor mutation burden achieving complete response to pembrolizumab monotherapy

ER阳性、HER2阴性转移性乳腺癌一例:高肿瘤突变负荷患者对帕博利珠单抗单药治疗实现完全缓解

2026-05-010
PRE
Honda et al. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype. (vol 8 , pg 1522 , 2022)

本田等. 超快速MRI在评估新辅助全身治疗后残留乳腺癌中的视觉评价:一项与亚型相关的初步研究. (卷 8, 页 1522, 2022)

2026-01-060
OAAI
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

ER阳性、HER2阴性原发性乳腺癌的辅助S-1联合内分泌治疗:POTENT试验后的预后调查

2025-10-240
OA
Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: A matched analysis of the Japanese National Clinical Database-Breast Cancer Registry

比较生物亚型下乳腺癌鳞状细胞癌患者与浸润性导管癌患者的生存情况:基于日本国家临床数据库-乳腺癌登记系统的匹配分析

2025-08-270
OAAI
Detection capability of the Medical Imaging Projection System for sentinel lymph node biopsy in patients with breast cancer with and without neoadjuvant chemotherapy: a retrospective study

医学成像投影系统对接受和不接受新辅助化疗的乳腺癌患者行前哨淋巴结活检的检测能力:一项回顾性研究

2025-05-100
OA
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy☆

PENELOPE-B试验的最终生存结果,该试验探讨了帕博西利(palbociclib)与安慰剂对比用于新辅助化疗后具有高危HR+/HER2−乳腺癌且存在残留病灶患者的治疗。

2025-03-240
PRE
Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells

前列腺素E2-EP2/EP4信号通过损害免疫细胞中的生物能学和核糖体生物合成来诱导人类癌症的免疫抑制

2024-11-010
OAAI
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer

CAPItello-291研究的简明语言摘要: 激素受体阳性的晚期乳腺癌中的Capivasertib

2024-09-162
OAAI